
DBVT Stock Forecast & Price Target
DBVT Analyst Ratings
Bulls say
DBV Technologies is supported by a clear regulatory catalyst path for Viaskin Peanut, with BLA acceptance for children aged 4–7 expected in 4Q26 and a potential Priority Review that could materially shorten timelines versus standard review. Its fundamental appeal is reinforced by strong commercial potential, including projected peak sales of about $3B, while the company’s $165.7M to $166M cash balance provides runway into 3Q27 and helps fund launch preparation. Although manufacturing and CMC issues at Fareva Amboise create near-term overhang, management says they are remediation-related rather than product-defect related, and the sequential toddler filing strategy could improve review efficiency and support broader approval momentum.
Bears say
DBV Technologies is facing a negative fundamental outlook because its lead peanut allergy program has been hit by delays in BLA submission for both children and toddlers, alongside new adverse findings in the COMFORT-TODDLER study and other R&D, regulatory, or commercial setbacks. The company also faces meaningful clinical and regulatory risk, since success in VITESSE is needed to support a BLA in 4–7-year-olds, while accelerated approval in 1–3-year-olds depends on a confirmatory trial after approval. Financially, DBV is expected to continue net losses at least until commercialization and likely through the early launch phase, with a need to raise additional capital that could dilute shareholders, while variable desensitization and uncertain real-world protection weaken the commercial case for Viaskin Peanut.
This aggregate rating is based on analysts' research of DBV Technologies SA Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.
DBVT Analyst Forecast & Price Prediction
Start investing in DBVT
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About DBV Technologies SA Sponsored ADR (DBVT) Forecast
DBVT Analyst Forecast & Price Prediction
Start investing in DBVT
Order type
Buy in
Order amount
Est. shares
0 shares